Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-1723

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters ; volume:10 ; number:1 ; day:18 ; month:6 ; year:2019 ; pages:1-11 ; date:12.2019
Nature Communications ; 10, Heft 1 (18.6.2019), 1-11, 12.2019

Creator: Lee, Yong Gu
Chu, Haiyan
Lu, Yingjuan
Leamon, Christopher P.
Srinivasarao, Madduri
Putt, Karson S.
Low, Philip S.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-019-10565-7

URN: urn:nbn:de:101:1-2019090609534160154491

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lee, Yong Gu
Chu, Haiyan
Lu, Yingjuan
Leamon, Christopher P.
Srinivasarao, Madduri
Putt, Karson S.
Low, Philip S.
SpringerLink (Online service)

Other Objects (12)

Cytokine release syndrome

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Cytokine release syndrome after bronchoalveolar lavage

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

Cytokine release syndrome: grading, modeling, and new therapy

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Cytokine release syndrome

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Cytokine release syndrome after bronchoalveolar lavage

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

Cytokine release syndrome: grading, modeling, and new therapy

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Cytokine release syndrome

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Cytokine release syndrome after bronchoalveolar lavage

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

Cytokine release syndrome: grading, modeling, and new therapy

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Cytokine release syndrome

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Cytokine release syndrome after bronchoalveolar lavage

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

Cytokine release syndrome: grading, modeling, and new therapy

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Cytokine release syndrome

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Cytokine release syndrome after bronchoalveolar lavage

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

Cytokine release syndrome: grading, modeling, and new therapy

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Cytokine release syndrome

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

Cytokine release syndrome after bronchoalveolar lavage

Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

Cytokine release syndrome: grading, modeling, and new therapy

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

Related objects

Reset password